Perfusion MRI for Kidney Cancer

Recruiting in Palo Alto (17 mi)

Overseen byDavid Foran, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Rutgers, The State University of New Jersey

No Placebo Group

Trial Summary

What is the purpose of this trial?

This pilot clinical trial studies perfusion magnetic resonance imaging in diagnosing patients with kidney tumors. Diagnostic procedures, such as perfusion magnetic resonance imaging, may help find and diagnose kidney tumors and predict and monitor a patient's response to treatment.

Eligibility Criteria

This trial is for adults with kidney tumors at least 1 cm in size, which can be non-metastatic or metastatic. Participants must understand and sign a consent form. Women of childbearing age need a negative pregnancy test. Those with severe diseases, poor kidney function (eGFR < 45), pregnant or breastfeeding women, and individuals unable to undergo MRI due to claustrophobia or metal implants are excluded.

Inclusion Criteria

Patients must be able to read, understand, and voluntarily sign an informed consent document

My kidney tumor is at least 1 cm big and hasn't spread, based on scans.

I have kidney cancer that has spread, but not to my lungs.

See 3 more

Exclusion Criteria

You have a known allergy to the contrast agent used for intravenous imaging.

I am not pregnant or breastfeeding.

Severe concurrent disease, infection, or medical co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment

See 2 more

Treatment Details

Interventions

Arterial Spin Labeling Magnetic Resonance Imaging (Procedure)
Dynamic Contrast-Enhanced Magnetic Resonance Imaging (Procedure)
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (Procedure)
Perfusion Magnetic Resonance Imaging (Procedure)

Trial OverviewThe study tests perfusion magnetic resonance imaging (MRI) techniques like Dynamic Susceptibility Contrast-Enhanced MRI and Arterial Spin Labeling MRI to diagnose kidney tumors and monitor treatment response. It's designed for patients who may have localized or spread cancer.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Diagnostic (pMRI)Experimental Treatment4 Interventions

Patients undergo DCE, DSC, or ASL pMRI within 30 days of biopsy or surgery. Patients with organ confined tumors selected for active surveillance or surgery and patients with metastatic renal cell carcinoma undergo follow up pMRI at 1-6 months.